Maxim Group analyst Jason McCarthy assigned a Buy rating to Achieve Life Sciences (ACHV – Research Report) yesterday and set a price target of $21.00. The company’s shares closed last Friday at $10.23, close to its 52-week low of $4.51.
According to TipRanks.com, McCarthy is a top 100 analyst with an average return of 30.2% and a 51.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Achieve Life Sciences with a $60.50 average price target.
The company has a one-year high of $48.60 and a one-year low of $4.51. Currently, Achieve Life Sciences has an average volume of 560K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.